#61
|
||||
|
||||
FDA îäîáðèë òåìïëèçóìàá ( àíòèòåëî ê ÑD3) äëÿ îòñðî÷êè ïðîãðåññèðîâíèÿ ÑÄ1
__________________
Ã.À. Ìåëüíè÷åíêî |
#62
|
||||
|
||||
Î êàê! Åñëè íå îøèáàþñü, ýòî âîîáùå ïåðâûé ïðåïàðàò, îäîáðåííûé äëÿ ýòîé öåëè.
"Ïåðâàÿ ëàñòî÷êà". Ãëÿäèøü, è ñêðèíèíã ïðèãîäèòñÿ...
__________________
×òîáû ïîñòàâèòü äèàãíîç íåïðàâèëüíî, íàäî èìåòü îñîáûé òàëàíò è ïðåìíîãî ïîñòàðàòüñÿ: ñäåëàòü ÌÐÒ è ÊÒ âñåõ ëþáîïûòíûõ ìåñò áîëüíîãî, ðåíòãåíîâñêèå ñíèìêè îò ãîëîâû äî ïÿò, àíàëèçû âñåõ áèîæèäêîñòåé, ïðèãëàñèòü ïÿòîê-äðóãîé êîíñóëüòàíòîâ… Ñàì ÷åðò ïîòîì âî âñåì ýòîì íå ðàçáåðåòñÿ! Ï. Ðóäè÷ |
#63
|
|||
|
|||
|
#64
|
||||
|
||||
Ïðè÷óäëèâî òàñóåòñÿ êîëîäà.
Óæå ïî÷òè ïîçàáûòûé ñèáóòðàìèí ( à ñêîëüêî âñåãî áûëî!) çàìåí¸í ìëàäøèì î÷åíü øóñòðûì áðàòöåì òåçîôåíçèíîì, ïðè÷¸ì äëÿ î÷åíü êðóòîé ãðóïïû - ãèïîòàëàìè÷åñêîå îæèðåíèå, à ÷òîá ñåðäå÷êî íå âûñêàêèâàëî, çàïîëèðîâàëè ìåòîïðîëîëîì, Ê Íuynh è äð, 2022
__________________
Ã.À. Ìåëüíè÷åíêî |
#65
|
||||
|
||||
Íó, â Ðîññèè ñèáóòðàìèí îòíþäü íå çàáûò, ìëàäûå äàìû ðîñêîøíûõ ðàçìåðîâ îòêàçûâàþòñÿ âûõîäèòü èç êàáèíåòà ýíäîêðèíîëîãà, íå ïîëó÷èâ âîæäåëåííûé ðåöåïòèê. Åæåíåäåëüíî õîòü îäíà, äà åñòü. Ñîãëàñíû äàæå íà âûñêàêèâàþùåå ñåðäå÷êî è ïîâûøåííîå ÀÄ (õîòÿ èäåÿ "çàïîëèðîâàòü ìåòîïðîëîëîì" ñâåæà è çàìàí÷èâà).
Íà àãîíèñòû ÃÏÏ-1 íå ñîãëàøàþòñÿ, õîòÿ ïðè ïîêóïêå îíûõ ïîõóäååøü óæå òîëüêî îò òîãî, ÷òî íà åäó äåíåã íå îñòàíåòñÿ. Ïî÷èòàåì ïðî òåçîôåíçèí, ãëÿäèøü, äîéäåò è äî íàñ ïðåïàðàò (åñëè íå îòìåíèòñÿ ïðåæäå, à òî ñêîëüêî óæ èõ, öåíòðàëüíîãî äåéñòâèÿ, áûëî...).
__________________
×òîáû ïîñòàâèòü äèàãíîç íåïðàâèëüíî, íàäî èìåòü îñîáûé òàëàíò è ïðåìíîãî ïîñòàðàòüñÿ: ñäåëàòü ÌÐÒ è ÊÒ âñåõ ëþáîïûòíûõ ìåñò áîëüíîãî, ðåíòãåíîâñêèå ñíèìêè îò ãîëîâû äî ïÿò, àíàëèçû âñåõ áèîæèäêîñòåé, ïðèãëàñèòü ïÿòîê-äðóãîé êîíñóëüòàíòîâ… Ñàì ÷åðò ïîòîì âî âñåì ýòîì íå ðàçáåðåòñÿ! Ï. Ðóäè÷ |
#66
|
|||
|
|||
|
#67
|
||||
|
||||
Ðàäóåò ïîÿâëåíèå â íàøåì àðñåíàëå ( îáùå÷åëîâå÷åñêîì) ïðåïàðàòà ñåëèöèêëèá êàê íåïîñðåäñòâåííî âëèÿþùåãî íà êîðòèêîòðîôû
__________________
Ã.À. Ìåëüíè÷åíêî |
#68
|
||||
|
||||
The FDA "identified deficiencies" in Ascendis Pharma's new drug application for its hypoparathyroidism drug palopegteriparatide (TransCon PTH)opens in a new tab or window, putting new labeling and post-marketing discussions on hold for now, the developer said.
__________________
Ã.À. Ìåëüíè÷åíêî |
#69
|
||||
|
||||
Äâå íîâîñòè, êàê â àíåêäîòå
. Monthly supplementation with 60,000 IU of oral vitamin D3opens in a new tab or window for older adults didn't appear to increase or decrease overall fracture risk over a 5-year period. The same held true for non-vertebral, major osteoporotic, and hip fractures. (The Lancet Diabetes & Endocrinology) Teprotumumab (Tepezza)opens in a new tab or window led to a significantly greater reduction in proptosis over placebo in people with chronic thyroid eye disease for an average of 5 years and low levels of disease activity (2.41 vs 0.92 mm, p=0.0004), Horizon announced with its phase IV trial results.
__________________
Ã.À. Ìåëüíè÷åíêî |
#70
|
||||
|
||||
Íàñêîëüêî ÿ ïîìíþ, íàòèâíûé Ä3 êàê àíòèîñòåîïîðîòè÷åñêèé ïðåïàðàò îñîáî è íå ïîçèöèîíèðîâàëñÿ...  ýòîì ïëàíå áîëüøå èíòåðåñà áûëî ê àêòèâíûì ôîðìàì âèòàìèíà Ä.
À Òåïåççà ðàäóåò. Òåïåðü áû íàçâàíèå ïîáëàãîçâó÷íåå è ðåãèñòðàöèþ â Ðîññèè.
__________________
×òîáû ïîñòàâèòü äèàãíîç íåïðàâèëüíî, íàäî èìåòü îñîáûé òàëàíò è ïðåìíîãî ïîñòàðàòüñÿ: ñäåëàòü ÌÐÒ è ÊÒ âñåõ ëþáîïûòíûõ ìåñò áîëüíîãî, ðåíòãåíîâñêèå ñíèìêè îò ãîëîâû äî ïÿò, àíàëèçû âñåõ áèîæèäêîñòåé, ïðèãëàñèòü ïÿòîê-äðóãîé êîíñóëüòàíòîâ… Ñàì ÷åðò ïîòîì âî âñåì ýòîì íå ðàçáåðåòñÿ! Ï. Ðóäè÷ |
#71
|
||||
|
||||
Compared with oral bisphosphonates, denosumab (Prolia, Xgeva)opens in a new tab or window was linked with a lower risk for developing type 2 diabetes in adults age 45 and older with osteoporosis. (The BMJ)
The thyroid eye disease drug teprotumumab (Tepezza)opens in a new tab or window is indicated for use in patients with any level of disease activity or duration according to an FDA-cleared label update, said drugmaker Horizon Therapeutics.
__________________
Ã.À. Ìåëüíè÷åíêî |
#72
|
||||
|
||||
Òåïåççà ðàäóåò âñå áîëüøå è áîëüøå.
Ïðèÿòíûé ôàêò î Ïðîëèà.
__________________
×òîáû ïîñòàâèòü äèàãíîç íåïðàâèëüíî, íàäî èìåòü îñîáûé òàëàíò è ïðåìíîãî ïîñòàðàòüñÿ: ñäåëàòü ÌÐÒ è ÊÒ âñåõ ëþáîïûòíûõ ìåñò áîëüíîãî, ðåíòãåíîâñêèå ñíèìêè îò ãîëîâû äî ïÿò, àíàëèçû âñåõ áèîæèäêîñòåé, ïðèãëàñèòü ïÿòîê-äðóãîé êîíñóëüòàíòîâ… Ñàì ÷åðò ïîòîì âî âñåì ýòîì íå ðàçáåðåòñÿ! Ï. Ðóäè÷ |
#73
|
||||
|
||||
SEATTLE -- Adding beta-hydroxybutyrate (BHB) stopping criteria cut down fasting time when detecting insulinomas in patients with hypoglycemia, according to late-breaking findings presented here.
By adding in a stopping point if BHB reached a level of 2.7 mmol/L or higher to the fasting protocol, fasting time was nearly 8 hours shorter on average across the board, said Michelle D. Lundholm, MD, of the Cleveland Clinic. With this update to the protocol, the average fast duration lasted only 49.7±21.1 hours, she said during a presentation at the American Association of Clinical Endocrinologyopens in a new tab or window (AACE) annual meeting. âîò òîëüêî íå ïîéìó, êàê ýòî â äåíüãàõ
__________________
Ã.À. Ìåëüíè÷åíêî |
#74
|
||||
|
||||
 ïðèíöèïå èññëåäîâàíèå âíåäðåíî - íî êìí Þêèíà íàïèñàëà ìíå, ÷òî íå ñòîèò ïî áåòà- ãèäðîêñèáóòèðàòó îñòàíàâëèâàòü ïðîáó, ïîåëèêó íå òîëüêî èíñóëèíîìà íàñ âîëíóåò. Ïîêà íå çíàþ
__________________
Ã.À. Ìåëüíè÷åíêî |
#75
|
|||
|
|||
Î ìåòôîðìèíå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |